Skip to main content
SpringerLink
Log in

Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohn’s Disease

A Practical Approach

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Crohn’s disease is a chronic, disabling, inflammatory condition of the gastrointestinal tract that has a segmental distribution and can affect the entire gastrointestinal tract. Treatment of patients with Crohn’s disease represents a difficult challenge to physicians. Conventional therapy includes corticosteroids and immunosuppressants. Corticosteroids are highly effective for inducing response and remission, but the results in the long-term are disappointing and are associated with serious adverse events. Immunosuppressants are effective, but have a slow onset of action and are associated with intolerance and adverse events. In the last decade, as a result of a better understanding of the immunopathology of inflammatory bowel disease, novel therapeutic agents have been developed to target crucial components of the inflammatory cascade. Tumour necrosis factor (TNF) inhibitors (infliximab, adalimumab and certolizumab pegol) offer an effective alternative therapy, and are widely used in clinical practice for the management of Crohn’s disease and ulcerative colitis. This article focuses on the latest evidence-based data on clinical effectiveness, mucosal healing, immunogenicity, dose optimization for induction and maintenance of response and remission, and step-up versus top-down approaches of the available TNF inhibitors for the treatment of Crohn’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417–29

    Article  PubMed  CAS  Google Scholar 

  2. Schreiber S, Reinisch W, Colombel JF, et al. Early Crohn’s disease shows high levels of remission to therapy with adalimumab: subanalysis of CHARM. Gastroenterology 2007; 132: A–147

    Google Scholar 

  3. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55 Suppl.: i16–35

    Article  PubMed  Google Scholar 

  4. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatories du Tube Digestif (GETAID). Gut 1989; 30: 983–9

    CAS  Google Scholar 

  5. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981–7

    Article  PubMed  CAS  Google Scholar 

  6. Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut 1997; 40: 443–8

    PubMed  Google Scholar 

  7. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993; 94: 174–81

    Article  PubMed  CAS  Google Scholar 

  8. Panés J, Gomollón F, Taxonera C, et al. Crohn’s disease: a review of current treatment with a focus on biologics. Drugs 2007; 67: 2511–37

    Article  PubMed  Google Scholar 

  9. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005; 128: 862–9

    Article  PubMed  CAS  Google Scholar 

  10. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology 2008; 135: 1493–9

    Article  PubMed  CAS  Google Scholar 

  11. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009; 58: 492–500

    Article  PubMed  CAS  Google Scholar 

  12. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029–35

    Article  PubMed  CAS  Google Scholar 

  13. Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761–9

    Article  PubMed  CAS  Google Scholar 

  14. Hanauer SB, Feagan BG, Lichtenstein GR, et al., ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9

    Article  PubMed  CAS  Google Scholar 

  15. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398–405

    Article  PubMed  CAS  Google Scholar 

  16. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876–85

    Article  PubMed  CAS  Google Scholar 

  17. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009; 136: 441–50

    Article  PubMed  CAS  Google Scholar 

  18. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–33

    Article  PubMed  CAS  Google Scholar 

  19. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56: 1232–9

    Article  PubMed  CAS  Google Scholar 

  20. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 52–65

    Article  PubMed  CAS  Google Scholar 

  21. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829–38

    PubMed  Google Scholar 

  22. Sandborn WJ, Feagan BG, Stoinov S, et al., PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357: 228–38

    Article  PubMed  CAS  Google Scholar 

  23. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al., PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007; 357: 239–50

    Article  PubMed  CAS  Google Scholar 

  24. Clark M, Colombel JF, Feagan BG, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology 2007; 133: 312–39

    Article  PubMed  Google Scholar 

  25. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2008; (1): CD006893

  26. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 935–87

    Article  PubMed  Google Scholar 

  27. Loras C, Saro C, Gonzalez-Huix F, et al. GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104: 57–63

    CAS  Google Scholar 

  28. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 7: 947–53

    Google Scholar 

  29. Frøslie KF, Jahnsen J, Moum BA, et al., IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412–22

    Article  PubMed  Google Scholar 

  30. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease: evolution on prednisolone. Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811–8

    CAS  Google Scholar 

  31. Olaison G, Sjödahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31: 325–8

    Article  PubMed  CAS  Google Scholar 

  32. D’Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667–71

    Article  PubMed  Google Scholar 

  33. D’Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 1997; 112: 1475–81

    Article  PubMed  Google Scholar 

  34. Lémann M, Mary JY, Colombel JF, et al. Groupe D’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812–8

    Google Scholar 

  35. Colombel JF, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease na:ve to immunomodulators and biologic therapy. Gut 2008; 57: A1

    Google Scholar 

  36. D’Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999; 116: 1029–34

    Article  PubMed  Google Scholar 

  37. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006; 63: 433–42

    Article  PubMed  Google Scholar 

  38. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009; 15: 1295–301

    Article  PubMed  Google Scholar 

  39. Rutgeerts P, D’Haens GR, Van Assche G, et al. Adalimu-mab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn’s disease: first results of the extend trial. Gastroenterology 2009; 136: A–116

    Article  Google Scholar 

  40. Hébuterne X, Colombel J, Bouhnik Y, et al. Endoscopic improvement in patients with active Crohn’s disease treated with certolizumab pegol: first results of the MUSIC clinical trial. Gut 2008; 57: A–15

    Google Scholar 

  41. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601–8

    Article  PubMed  CAS  Google Scholar 

  42. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007; 56: 1226–31

    Article  PubMed  CAS  Google Scholar 

  43. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003; 124: 917–24

    Article  PubMed  CAS  Google Scholar 

  44. Hanauer SB, D’Haens GR, Colombel JF, et al. Sustained clinical remission in patients with moderate to severe Crohn’s disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressant therapy. Am J Gastroenterol 2006; 101: S457

    Google Scholar 

  45. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 2009; 137: 1628–40

    Article  PubMed  CAS  Google Scholar 

  46. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 402–13

    Article  PubMed  CAS  Google Scholar 

  47. Domènech E, Zabana Y, Mañosa M, et al. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. J Clin Gastroenterol. Epub 2009 May 4

  48. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2: 542–53

    Article  PubMed  CAS  Google Scholar 

  49. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial. Am J Gastroenterol 2009; 104: 1170–9

    Article  PubMed  CAS  Google Scholar 

  50. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohn’s disease. Inflamm Bowel Dis 2007; 13: 1093–9

    Article  PubMed  Google Scholar 

  51. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104: 760–7

    Article  PubMed  CAS  Google Scholar 

  52. Schnitzler F, Fidder H, Ferrante M, et al. Flexible dosing of infliximab enables long-term maintenance of response in patients with refractory Crohn’s disease. Gut 2008; 57: A65

    Google Scholar 

  53. Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009; 29: 416–23

    Article  PubMed  CAS  Google Scholar 

  54. Toruner M, Loftus EV, Harmesen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929–36

    Article  PubMed  Google Scholar 

  55. Beigel F, Jürgens M, Tillack C, et al. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease. Nat Rev Gastroenterol Hepatol 2009; 6: 433–6

    Article  PubMed  Google Scholar 

  56. Feagan BG, McDonald JW, Panaccione R, et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn’s disease. Gastroenterology 2008; 135: 294–5

    Article  Google Scholar 

  57. Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861–8

    Article  PubMed  Google Scholar 

  58. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome alter scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 2006; 4: 1248–54

    Article  PubMed  CAS  Google Scholar 

  59. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000; 119: 895–902

    Article  PubMed  CAS  Google Scholar 

  60. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005; 54: 237–41

    Article  PubMed  CAS  Google Scholar 

  61. Lémann M, Mary JY, Duclos B, et al. Groupe d’Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054–61

    Google Scholar 

  62. D’Haens G, Baert F, van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371: 660–7

    Article  PubMed  Google Scholar 

  63. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology 2006; 130: 650–6

    Article  PubMed  Google Scholar 

  64. Papi C, Festa V, Leandro G, et al. Long-term outcome of Crohn’s disease following corticosteroid-induced remission. Am J Gastroenterol 2007; 102: 814–9

    Article  PubMed  CAS  Google Scholar 

  65. Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol 2008; 43: 948–54

    Article  PubMed  CAS  Google Scholar 

  66. Schreiber S, Hanauer S, Lichtenstein G, et al. Superior efficacy of certolizumab pegol in early Crohn’s disease is independent of CRP status. Gastroenterology 2007; 132: A–510

    Google Scholar 

Download references

Acknowledgements

M.J. Etchevers and I. Ordás contributed equally to this work. No sources of funding were used in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Gastroenterology Department, Hospital Clinic i Provincial, CIBER-EHD, C/Villarroel, 170, Barcelona, 08036, Spain

    Maria Josefina Etchevers, Ingrid Ordás & Elena Ricart MD PhD

Authors
  1. Maria Josefina Etchevers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingrid Ordás
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena Ricart MD PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elena Ricart MD PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Etchevers, M.J., Ordás, I. & Ricart, E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohn’s Disease. Drugs 70, 109–120 (2010). https://doi.org/10.2165/11533700-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11533700-000000000-00000

Keywords

Search

Navigation